Literature DB >> 6781220

A simple method for the production of F(ab')2 preparations by pepsin digestion of total serum protein.

F Poulsen, T Hjort.   

Abstract

An easy and rapid method for producing F(ab')2 fragments by pepsin treatment of total serum protein is described. No further purification of the hydrolysate was used. Most serum proteins were degraded to small peptides which were removed by dialysis, the preparations thus being relatively rich in F(ab')2 fragments. The degree of hydrolysis was determined by means of an antiserum against the part of the gamma-chain which is degraded by pepsin. Under optimal conditions for hydrolysis, unsplit IgG could not be detected by double immunodiffusion. Using sperm-agglutinating and immobilizing sera, the F(ab')2 preparations could be characterized functionally. After hydrolysis the agglutinating activity was relatively unchanged, whereas the immobilizing activity had vanished.

Mesh:

Substances:

Year:  1980        PMID: 6781220     DOI: 10.1111/j.1699-0463.1980.tb00101.x

Source DB:  PubMed          Journal:  Acta Pathol Microbiol Scand C        ISSN: 0304-1328


  4 in total

1.  Serum antibodies against central nervous system proteins in human demyelinating disease.

Authors:  J Newcombe; S Gahan; M L Cuzner
Journal:  Clin Exp Immunol       Date:  1985-02       Impact factor: 4.330

2.  Monoclonal antibodies against Aleutian disease virus distinguish virus strains and differentiate sites of virus replication from sites of viral antigen sequestration.

Authors:  R E Race; B Chesebro; M E Bloom; B Aasted; J Wolfinbarger
Journal:  J Virol       Date:  1986-01       Impact factor: 5.103

3.  Reaction against liver cells by human antiactin antibodies purified by affinity chromatography.

Authors:  K Riison; H Diederichsen; I Andersen
Journal:  J Clin Pathol       Date:  1982-07       Impact factor: 3.411

4.  Macrophage Fc receptors control infectivity and neutralization of canine distemper virus-antibody complexes.

Authors:  M J Appel; S G Mendelson; W W Hall
Journal:  J Virol       Date:  1984-09       Impact factor: 5.103

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.